SHARON BARBARI
CIK 1240499 · EVP, Finance & CFO · last filed 2025-12-15
SHARON BARBARI is an EVP, Finance & CFO who has filed 48 SEC Form 4 insider transactions across 9 companies since 2007. The most recent filing, for VYNE, was dated Dec 15, 2025. Current disclosed insider exposure totals $3.0M across reported positions. 17 SEC filings were submitted jointly with Oculus Innovative Sciences, Inc.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.97M
9
48
$0
Filer Profile
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VYNE Therapeutics Inc. (VYNE) Delisted | Director | — | $28.56 | — | $0 | 6 | 2025-12-15 |
| AGILE THERAPEUTICS INC (AGRX) Delisted | Director | 974 | $1.51 | $1.5K | $0 | 4 | 2023-06-09 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Director | 75,000 | — | — | $0 | 4 | 2020-08-21 |
| Foamix Pharmaceuticals Ltd. (FOMX) Delisted | Director | — | — | — | $0 | 1 | 2019-05-20 |
| Sonoma Pharmaceuticals, Inc. (SNOAW) Delisted | Director | 43,417 | — | — | $0 | 6 | 2018-03-02 |
| CYTK | EVP, Finance & CFO | 40,323 | $73.62 | $2.97M | $0 | 15 | 2017-03-02 |
| Sonoma Pharmaceuticals, Inc. (OCLSW) Delisted | Director | 6,244 | — | — | $0 | 1 | 2016-11-30 |
| Sonoma Pharmaceuticals, Inc. (OCLS) Delisted | Director | 5,209 | — | — | $0 | 4 | 2016-08-30 |
| Sonoma Pharmaceuticals, Inc. (OCLS.W) Delisted | Director | 4,356 | — | — | $0 | 5 | 2016-03-02 |
Recent Filings
48 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-12-15 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-12-13 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-08-26 | — | Disp (D) | −973 | -$1.5K | |
| 2024-01-03 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-12-15 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-09 | AGILE THERAPEUTICS INC (AGRX) Delisted | Grant (A) | +935 | $0 | EDGAR |
| 2022-08-12 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-10 | AGILE THERAPEUTICS INC (AGRX) Delisted | Grant (A) | +670 | $0 | EDGAR |
| 2021-07-20 | VYNE Therapeutics Inc. (VYNE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-10 | AGILE THERAPEUTICS INC (AGRX) Delisted | Grant (A) | +24,510 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.